Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.64 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GABRP | O00591 | 1/20 | 0.50 |
| ▸ | GABRD | O14764 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6123384 | 0.91 | DYRK1A (0.51) | DYRK1AMAOAGABRA1GABRG2GABRB3 | |
| SCHEMBL2721137 | 0.89 | DYRK1A (0.50) | DYRK1AMAOAGABRA1GABRG2GABRB3 | |
| SCHEMBL6123267 | 0.87 | DYRK1A (0.66) | DYRK1AMAOAGABRA1GABRG2GABRB3 | |
| SCHEMBL2721485 | 0.86 | MAOA (0.67) | DYRK1AMAOAGABRA1GABRG2GABRB3 | |
| SCHEMBL2719601 | 0.83 | ROCK2 (0.49) | DYRK1AMAOAGABRA1GABRG2GABRB3 | |
| SCHEMBL2730157 | 0.83 | ROCK2 (0.44) | DYRK1AMAOAGABRA1GABRG2GABRB3 | |
| SCHEMBL6123438 | 0.83 | GRIN2D (0.52) | DYRK1AMAOAGABRA1GABRG2GABRB3 | |
| SCHEMBL2730361 | 0.83 | MAOA (0.55) | DYRK1AMAOAGABRA1GABRG2GABRB3 | |
| SCHEMBL6122809 | 0.80 | CCNB2 (0.60) | DYRK1AMAOAGABRA1GABRG2GABRB3 | |
| SCHEMBL6123249 | 0.80 | TDO2 (0.57) | DYRK1AMAOAGABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274258-A1 | CARBAZOLE AND CARBOLINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF | PHILIP MORRIS PRODUCTS S.A. (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274258-A1 | CARBAZOLE AND CARBOLINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF | PHILIP MORRIS PRODUCTS S.A. (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274258-A1 | CARBAZOLE AND CARBOLINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF | PHILIP MORRIS PRODUCTS S.A. (CH) | 2013-10-17 | — | — | US | disclosed |
| EP-2455378-A1 | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof | Philip Morris Products S.A. (CH) | 2012-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274258-A1 | CARBAZOLE AND CARBOLINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF | CCNI, CCNY, CYCS | DYRK1A 1286/4885MAOA 1701/4885GABRA1 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.